MedPath

Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System

Terminated
Conditions
Heart Failure
Atrial Fibrillation
Cardiac Resynchronization Therapy
Interventions
Device: CRT-DX
Registration Number
NCT04870281
Lead Sponsor
Biotronik, Inc.
Brief Summary

The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of patient outcomes between AF subtypes.

Detailed Description

There is a need for more evidence about the benefits of Cardiac Resynchronization Therapy (CRT) in a patient population with heart failure and atrial fibrillation. The BIO-AffectDX Study will gather information about adults with heart failure and atrial fibrillation who are treated with a CRT-DX device from many locations across the United States. The BIO-AffectDX Study will look at the results of treatment in participants with the primary goal to evaluate the improvement in overall health prior to device implant through 12 months. Overall health will be measured by your study doctor for AF improvement, physical fitness, and general quality of life.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • Standard CRT-D indication according to current guidelines
  • Patient has documented history of paroxysmal, persistent, or long-standing persistent atrial fibrillation
  • De novo implant or upgrade from a DX implantable cardioverter-defibrillator (ICD) system
  • Implant planned to occur within 30 days of consent
  • Patient is able to understand English or Spanish
  • Patient is able to understand the nature of the study and provide informed consent
  • Patient is willing and able to complete all routine study visits at the investigational site for up to 12 months of follow-up
  • Patient is willing to utilize BIOTRONIK Home Monitoringยฎ via CardioMessenger
  • Patient age is greater than or equal to 18 years

After consent has been signed, additional inclusion criteria must be fulfilled for study participation:

  • Baseline subject assessment is evaluated as New York Heart Association class II, III or ambulatory IV heart failure at study Enrollment Visit
  • Baseline subject assessment of six-minute walk test is completed at study Enrollment Visit and walk distance โ‰ค 450 meters (1,476 feet)
Exclusion Criteria
  • Contraindication to CRT-D/CRT-DX
  • Patient has current or previous atrial pacing need
  • Patient is considered for a His Bundle Pacing system
  • Patient has current or previous pacemaker, non-DX ICD implant, or bi-ventricular pacing system prior to enrolling
  • Patient is currently planned for a pulmonary vein isolation catheter ablation procedure within 3 months of consent
  • Patient life expectancy is less than 1 year
  • Patient is expected to receive heart transplantation or ventricular assist device within 1 year after implant
  • Patient is expected to have a cardiac surgical procedure, such as coronary artery bypass graft or valve transcatheter replacement/repair or surgery, planned to occur within 6-months after implant (excludes atrioventricular node ablation procedures)
  • Patient is currently on dialysis, or is expected to receive dialysis within 1 year of implant
  • Patient is enrolled in any investigational cardiac device or drug trial that might significantly affect the studied outcomes
  • Any condition (e.g. severe arthritis, wheelchair bound, etc.) preventing the patient from performing the required six-minute walk test
  • Conditions that prohibit placement of any of the system leads
  • Patient reports pregnancy at the time of consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CRT-DX SystemCRT-DX-
Primary Outcome Measures
NameTimeMethod
Change in Clinical Composite Score from baseline12 months
Secondary Outcome Measures
NameTimeMethod
Change in six-minute walk distance from baseline for all patients and by atrial fibrillation sub-type6 and 12 months
Change in atrial fibrillation burden from baseline for all patients and by atrial fibrillation sub-type6 and 12 months
Change in quality of life questionnaires from baseline for all patients and by atrial fibrillation sub-type6 and 12 months
Rate of conversion to sinus rhythm12 months
Rate of composite all-cause death and heart failure12 months
Change in New York Heart Association class from baseline for all patients and by atrial fibrillation sub-type6 and 12 months
Change in Clinical Composite Score from baseline6 months
Rate of major complications12 months

Trial Locations

Locations (23)

Cardiology Associates Medical Group

๐Ÿ‡บ๐Ÿ‡ธ

Ventura, California, United States

AdventHealth Tampa

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

Glacier View Research Institute Cardiology

๐Ÿ‡บ๐Ÿ‡ธ

Kalispell, Montana, United States

Weill Cornell Medicine

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Cardiology Associates of North Mississippi

๐Ÿ‡บ๐Ÿ‡ธ

Tupelo, Mississippi, United States

Lenox Hill Hospital

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Michigan Heart

๐Ÿ‡บ๐Ÿ‡ธ

Ypsilanti, Michigan, United States

University of Kentucky - Gill Heart and Vascular Institute

๐Ÿ‡บ๐Ÿ‡ธ

Lexington, Kentucky, United States

Kansas City Heart Rhythm Institute

๐Ÿ‡บ๐Ÿ‡ธ

Overland Park, Kansas, United States

University of Michigan

๐Ÿ‡บ๐Ÿ‡ธ

Ann Arbor, Michigan, United States

Medical University of South Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

University of Cincinnati

๐Ÿ‡บ๐Ÿ‡ธ

Cincinnati, Ohio, United States

ProMedica Northwest Ohio Cardiology Consultants

๐Ÿ‡บ๐Ÿ‡ธ

Toledo, Ohio, United States

Massachusetts General Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Upstate Cardiology

๐Ÿ‡บ๐Ÿ‡ธ

Greenville, South Carolina, United States

Mercy Hospital Springfield

๐Ÿ‡บ๐Ÿ‡ธ

Springfield, Missouri, United States

Heart Rhythm Associates

๐Ÿ‡บ๐Ÿ‡ธ

Greenville, North Carolina, United States

Erlanger Institute for Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Chattanooga, Tennessee, United States

University of California San Diego - La Jolla

๐Ÿ‡บ๐Ÿ‡ธ

La Jolla, California, United States

Orlando Health Heart Institute

๐Ÿ‡บ๐Ÿ‡ธ

Orlando, Florida, United States

University of Iowa Hospitals and Clinics

๐Ÿ‡บ๐Ÿ‡ธ

Iowa City, Iowa, United States

Baptist Health Lexington

๐Ÿ‡บ๐Ÿ‡ธ

Lexington, Kentucky, United States

University of Kansas Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Kansas, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath